FindTrial
Sign In

A multi-center, prospective, randomized controlled trial of the efficacy of Marphalan combined with Daratumomab as a pretreatment regimen for autologous hematopoietic stem cell transplantation in the treatment of high-risk multiple myeloma

A multi-center, prospective, randomized controlled trial of the efficacy of Marphalan combined with Daratumomab as a pretreatment regimen for autologous hematopoietic stem cell transplantation in the treatment of high-risk multiple myeloma

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100052302
Enrollment
Unknown
Registered
2021-10-24
Start date
2021-11-01
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma

Interventions

Group A:malphalan combined with CD38 monoclonal antibody (daratumumab)
Group B:malphalan

Sponsors

Hematology Center of the First Affiliated Hospital of Xinjiang Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Aged 18 to 70 years; high-risk multiple myeloma patients with transplant indications, the risk stratification standard refers to Mayo mSMART version 3.0 important organs (mainly refers to the heart, liver, kidney, brain, etc.) Complications affecting transplantation; patients or family members who have signed informed consent.

Exclusion criteria

Exclusion criteria: Mentally ill patients.

Design outcomes

Primary

MeasureTime frame
blood routine;—

Countries

China

Contacts

Public ContactYuan Hailong

The First Affiliated Hospital of Xinjiang Medical University

1074913015@qq.com+86 13999961228

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026